In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Heron Therapeutics (HRTX – Research Report), with a price target of $9.00. The company’s shares closed yesterday at $1.73.
Byrnes covers the Healthcare sector, focusing on stocks such as Durect, Oncternal Therapeutics, and MiMedx Group. According to TipRanks, Byrnes has an average return of -8.1% and a 34.11% success rate on recommended stocks.
Heron Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $5.17.
See Insiders’ Hot Stocks on TipRanks >>
HRTX market cap is currently $259.6M and has a P/E ratio of -1.79.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HRTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Heron Therapeutics (HRTX) Company Description:
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.
Read More on HRTX:
- Biotech Alert: Searches spiking for these stocks today
- Heron Therapeutics price target lowered to $2.50 from $5.50
- Heron Therapeutics price target lowered to $4 from $5 at Needham
- Heron Therapeutics sees FY24 revenue $138M-$158M, consensus $156.57M
- Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
